Global pharmaceutical companies have demonstrated their immuno-oncology drugs’ effect in refractory solid tumors. Clinical results from major immuno-oncology drugs, including Imfinzi, Opdivo, and Yervoy, were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which kicked off last month in Chicago, U.S.

In the case of Imfinzi, the trial confirmed a survival benefit in small cell lung cancer. Imfinzi has shown promise in gastrointestinal cancers, including biliary tract and liver cancer. Such results paved the way for the company to add new indications.

The combination of Opdivo and Yervoy improved survival in the first-line treatment of liver canc